25 related articles for article (PubMed ID: 15057667)
1. Antidiabetic Bis-Maltolato-OxoVanadium(IV): conversion of inactive trans- to bioactive cis-BMOV for possible binding to target PTP-1B.
Scior T; Mack HG; García JA; Koch W
Drug Des Devel Ther; 2009 Feb; 2():221-31. PubMed ID: 19920909
[TBL] [Abstract][Full Text] [Related]
2. The influence of BMOV [bis(maltolato)oxovanadium(IV)] on biochemical and morphological alterations characteristic for streptozotocin-diabetic rat liver Golgi complexes.
Dabroś W; Dziga D; Kordowiak AM
Pol J Pathol; 2002; 53(4):205-13. PubMed ID: 12597338
[TBL] [Abstract][Full Text] [Related]
3. Influence of bis(maltolato)oxovanadium(IV) on activity of galactosyltransferase (GalT) and morphology of rat liver Golgi apparatus in control and streptozotocin diabetes.
Dabroś W; Kordowiak AM; Dziga D; Gryboś R
Pol J Pathol; 1998; 49(2):67-76. PubMed ID: 9798409
[TBL] [Abstract][Full Text] [Related]
4. The influence of a new vanadium compound, bis(2,2'-bipyridine)oxovanadium(IV) sulphate on liver golgi complexes from control and streptozotocin-diabetic rats.
Kordowiak AM; Dabroś W; Kajda B
Horm Metab Res; 2002 Oct; 34(10):556-60. PubMed ID: 12439783
[TBL] [Abstract][Full Text] [Related]
5. Biochemical and morphological alterations in rat liver Golgi complexes after treatment with bis(maltolato)oxovanadium(IV) [BMOV] or maltol alone.
Dabroś W; Dziga D; Gryboś R; Kordowiak AM
Pathol Res Pract; 2000; 196(8):561-8. PubMed ID: 10982019
[TBL] [Abstract][Full Text] [Related]
6. Sodium metavanadate affected control and streptozotocin-diabetic rat liver golgi complexes.
Dabroś W; Goc A; Turyna B; Kordowiak AM
Pol J Pathol; 2006; 57(2):91-7. PubMed ID: 17019971
[TBL] [Abstract][Full Text] [Related]
7. Streptozotocin-induced alterations in rat liver Golgi complexes are ameliorated by BMOV [Bis(maltolato)oxovanadium(IV)] activity.
Kordowiak AM; Dziga D; Dabroś W
Horm Metab Res; 2004 Mar; 36(3):148-54. PubMed ID: 15057667
[TBL] [Abstract][Full Text] [Related]
8. Vanadium treatment of type 2 diabetes: a view to the future.
Thompson KH; Lichter J; LeBel C; Scaife MC; McNeill JH; Orvig C
J Inorg Biochem; 2009 Apr; 103(4):554-8. PubMed ID: 19162329
[TBL] [Abstract][Full Text] [Related]
9. Bis(maltolato)-oxovanadium (IV)-induced phosphorylation of PKB, GSK-3 and FOXO1 contributes to its glucoregulatory responses (review).
Vardatsikos G; Mehdi MZ; Srivastava AK
Int J Mol Med; 2009 Sep; 24(3):303-9. PubMed ID: 19639221
[TBL] [Abstract][Full Text] [Related]
10. Increased potency of vanadium using organic ligands.
McNeill JH; Yuen VG; Dai S; Orvig C
Mol Cell Biochem; 1995 Dec 6-20; 153(1-2):175-80. PubMed ID: 8927036
[TBL] [Abstract][Full Text] [Related]
11. Vanadium: a review of its potential role in the fight against diabetes.
Badmaev V; Prakash S; Majeed M
J Altern Complement Med; 1999 Jun; 5(3):273-91. PubMed ID: 10381252
[TBL] [Abstract][Full Text] [Related]
12. Physiological roles of peroxido-vanadium complexes: Leitmotif as their signal transduction pathway.
Matsugo S; Kanamori K; Sugiyama H; Misu H; Takamura T
J Inorg Biochem; 2015 Jun; 147():93-8. PubMed ID: 25912243
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
